1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

AZ Centers Pearl As The Jewel Of Its Respiratory Franchise

 
• By Lisa LaMotta

The British pharma announced its proposed acquisition of Pearl Therapeutics, adding a late-stage COPD drug to its pipeline and a triple combo therapy to its mid-stage pipeline.

One week after pulling the plug on one of its few late-stage assets, AstraZeneca PLC has announced its intentions to acquire Pearl Therapeutics Inc. to get access to its late-stage chronic obstructive pulmonary disease treatment and its early-stage respiratory pipeline. The deal pleases analysts by fleshing out the larger company’s pipeline, but is still only a small step in its revitalization.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Aragen’s CEO Says NIH Funding Cut Means Less R&D Money, And Tariffs Would Add To Woes

 
• By Vibha Ravi

Aragen’s CEO Manni Kantipudi, who is keenly watching the Trump Administration’s moves on pharma tariffs, discusses funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, and talks with the Indian government to solve intellectual property challenges in an interview.

‘Come Early, Come Often,’ EMA Chief Tells Industry

 
• By Francesca Bruce

The European Medicines Agency’s chief, Emer Cooke, explained how the agency could help companies with their drug development plans, and said the EU Health Technology Assessment Regulation would help companies design clinical trials that are fit for regulators and HTA bodies.

Why Successful Companies Are ‘Tough On Themselves’ When It Comes To HTA

 
• By Eliza Slawther

Pharmaceutical companies need to “pressure test” their clinical development strategies early for health technology assessment purposes, particularly in light of the new EU HTA Regulation, a life sciences consultant says.